Edwards Lifesciences (EW) 10-Q2009 Q1 Quarterly report

Filed: 8 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AAA, accuracy, algorithm, aLifeStent, APB, arrangement, assigned, blood, Bulletin, cannula, carryforward, clarified, classification, collaboration, collaborative, collateral, collateralize, collateralized, commitment, contract, counterparty, default, deployed, DexCom, display, diversification, duration, endovascular, entered, entitled, ETlogix, event, exceed, existing, extent, FAS, firm, focused, frequency, glucose, graft, hardware, highly, hold, hospitalized, humanitarian, ill, improved, inception, inoperating, instrument, intellectual, interbank, intuitive, itsEndoDirect, itsIMR, itsLifepath, itsRetroFlex, joint, lift, location, longer, maximum, millionLifeStent, MIS, mitigate, national, outlined, percent, prevent, prohibited, prospective, protocol, publicly, Quantification, recoverable, Retrospective, royalty, SAB, scheme, scope, significantly, simpler, specialty, speculative, structural, successful, Swap, taxable, term, threshold, Topic, ultimately, unplanned, upfront, upgrade, variability, variable, variety, volatility, volume, weakening

Removed: acceptance, acquisition, addAscendra, adding, adjusted, administrative, advance, affirmative, andMagna, andPreSep, answered, applied, approach, artery, assessment, atraumatic, audit, byoperating, catheter, choose, close, combined, customized, delivered, derive, design, detection, discontinuation, discounted, disposition, distributed, doubtful, easily, employer, enableFloTrac, expecting, expire, expired, expiry, explained, external, funded, funding, general, havingascendra, implied, impracticable, initiated, introduced, involvement, IRS, itsPERIMOUNT, Japanese, margin, marketable, month, native, navigate, nonrefundable, obtain, obtained, ofRetroFlex, opportunity, overfunded, oximetry, Pension, physician, predominance, principal, proposed, pursue, quantity, range, readily, recognize, recovery, reimbursement, requirement, retained, revascularization, selling, senior, set, specific, spot, stenotic, subordinated, superficial, theascendra, theretroflex, tip, TMR, transact, transapical, transitioning, transmyocardial, unavailable, underfunded, unexpected, validated, yen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

EW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 32

EDWARDS LIFESCIENCES CORPORATION
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Edwards Lifesciences Corporation (the "Company") on Form 10-Q for the period ended March 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Michael A. Mussallem, Chairman of the Board and Chief Executive Officer of the Company, and Thomas M. Abate, Corporate Vice President, Chief Financial Officer and Treasurer, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


May 8, 2009				/s/ MICHAEL A. MUSSALLEM Michael A. Mussallem Chairman of the Board and Chief Executive Officer
May 8, 2009				/s/ THOMAS M. ABATE Thomas M. Abate Corporate Vice President, Chief Financial Officer and Treasurer (Chief Accounting Officer)

QuickLinks

Exhibit 32

EDWARDS LIFESCIENCES CORPORATION CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002